Physician profile
Reena Bansal
NPI 1366857187
$10,113.43
in general payments reported to CMS, 2019-2025
34 companies · $7,768 in 2025
The $7,768 reported for 2025 was more than what 94% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.49 · 2021: $414 · 2022: $281 · 2023: $740 · 2024: $897 · 2025: $7,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,700 · Food and Beverage: $2,530 · Travel and Lodging: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,699.98 |
| Food and Beverage | $2,530.07 |
| Travel and Lodging | $1,174.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,152.72 | 2022-2025 | |
| Glaxosmithkline, LLC. | $380.62 | 2021-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $264.53 | 2021-2025 | Breztri, Tezspire, Fasenra |
| Astellas Pharma US INC | $243.17 | 2024-2025 | Cresemba |
| Regeneron Healthcare Solutions, INC. | $206.89 | 2021-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $200.12 | 2023-2025 | Uptravi, Opsumit |
| Grifols USA, LLC | $194.70 | 2021-2024 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.78 | 2021-2024 | |
| Amgen INC. | $147.98 | 2020-2025 | Tezspire |
| Caris Mpi, INC. | $140.18 | 2025 | Mi Cancer Seek |
| United Therapeutics Corporation | $116.28 | 2022-2025 | Tyvaso, Tyvaso |
| Merck Sharp & Dohme LLC | $105.08 | 2021-2025 | Zerbaxa, Dificid, Recarbrio |
| Genzyme Corporation | $96.36 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $94.69 | 2023-2024 | |
| Electromed, INC. | $83.28 | 2024-2025 | Smartvest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $82.74 | 2024 | Yupelri |
| Viiv Healthcare Company | $47.80 | 2024 | Dovato, Rukobia |
| Csl Behring | $42.71 | 2023-2024 | Kcentra |
| Lilly USA, LLC | $35.14 | 2021 | |
| Verona Pharma, INC. | $34.40 | 2025 | Ohtuvayre |
| Ucb, INC. | $30.67 | 2025 | Bimzelx |
| Pulmonx Corporation | $26.34 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Viatris Specialty LLC | $26.30 | 2025 | Yupelri |
| Pfizer INC. | $24.95 | 2023 | |
| Advanced Respiratory, INC | $23.18 | 2021 | |
| Abiomed | $19.77 | 2025 | |
| Eisai INC. | $18.58 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $16.84 | 2025 | Lumryz |
| Tandem Diabetes Care, INC. | $16.34 | 2022 | |
| Cmp Pharma, INC. | $16.06 | 2025 | Atorvaliq, Carospir, Tadliq |
| Dova Pharmaceuticals | $15.87 | 2021 | |
| Philips North America LLC | $15.19 | 2025 | Incourage Airway Clearance Therapy |
| Exelixis INC. | $14.29 | 2021 | |
| 3b Medical, INC. | $9.88 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Bansal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.